dietary fiber
Multi-omics and artificial intelligence for precision drug discovery and potential clinical applications
3 June 2026
Liu Y, Zhu K, Peng W, Liu Z, Mao X.
Summary
What the study found
This research review highlights how combining massive biological datasets—including genetics, proteins, and metabolites—with artificial intelligence is revolutionizing the discovery of personalized medicines. By using AI to decode complex molecular patterns, scientists can identify new drug targets and predict treatment outcomes with much higher speed and accuracy.
Key findings
- Integrating multi-omics data provides a holistic view of disease mechanisms by mapping interactions between genes, proteins, and cellular waste products.
- Deep learning and artificial intelligence can identify latent patterns in biological data that are too complex for human researchers to detect manually.
- The use of virtual screening allows for the rapid testing of thousands of potential therapeutic compounds in a digital environment before entering a lab.
- This technological fusion enables precision medicine, allowing for the design of clinical trials tailored to the specific molecular profile of individual patients.
Practical takeaways
While this research focuses on drug discovery, the same "omics" technologies are increasingly used to develop personalized nutrition strategies tailored to your unique genetic and metabolic makeup. As these AI models evolve, they will likely provide highly specific guidance on which foods and lifestyle interventions best support your individual longevity and metabolic health.
Limitations
A major hurdle is the difficulty in harmonizing data from different biological sources to ensure consistent results across different populations. There are also concerns regarding algorithmic bias, which could lead to less accurate predictions for certain demographic groups if the underlying data is not diverse.
Abstract
The integration of multiomics technologies with artificial intelligence (AI) has become a transformative force in modern precision medicine, particularly within drug discovery. Multiomics approaches, including genome-wide association studies, transcriptomic profiling, proteomic interaction mapping, and metabolomic sequencing, provide unparalleled insights into the molecular dynamics of disease pathogenesis. Advanced AI methodologies, which leverage deep learning architectures, exhibit extraordinary capabilities in deciphering these intricate biological datasets, elucidating latent patterns, and constructing high-fidelity predictive models. The combined application of multiomics and AI has significant potential to accelerate target identification, streamline lead optimization processes, and enhance the precision of clinical trial designs. However, challenges persist, such as the need to harmonize disparate omics data streams, ensure reproducibility, and mitigate algorithmic biases. This review offers an in-depth analysis of multiomics applications across the drug development pipeline, covering target deconvolution, drug repositioning, and de novo compound discovery. It also explores the critical role of AI in drug discovery, focusing on virtual screening, pharmacokinetic modeling, and safety assessment frameworks. The fusion of multiomics with AI provides distinct advantages in hypothesis generation and data-driven discovery, opening new pathways for therapeutic innovation. By examining cases in oncology, neurodegenerative diseases, and cardiovascular conditions supported by robust technological infrastructures, this review presents a forward-thinking vision for future drug development. The convergence of these technologies not only enables comprehensive molecular understanding but also allows for more precise therapeutic interventions, marking the beginning of a new era in bench-to-clinic translational medicine.
Source study →